Our Mission:
Develop first-in-class Antibody-Drug-Conjugate therapeutics to provide meaningful treatments and cures to patients with metastatic and aggressive cancers.
A Boston-based Therapeutic Oncology Biotech
We utilize a proprietary Antibody-Discovery platform to generate antibodies to stem cell targets involved in cancer metastasis and utilize these new antibodies to develop Antibody-Drug-Conjugate therapeutics.
Targeted-Cancer Drug Development Strategy
Our targeted cancer drug development strategy is based on our belief that finding novel cancer targets is the solution to making better cancer drugs. We develop antibodies and ADCs to novel embryonic cancer targets-targets expressed in metastatic and aggressive cancers but not normal healthy tissues.
Antibody
We have developed a proprietary antibody platform and have generated a robust pipeline of antibodies to novel cancer targets. Our lead cancer drug, CM-14 is a First-in-Class Humanized ADC to treat patients with pancreatic and gastric cancers.
Next Steps
We are transitioning from a preclinical to a clinical biotech and preparations are underway to take CM-14 into a human clinical cancer trial.
To learn more about CureMeta and our lead ADC asset please review the
non-confidential deck below:
CureMeta Overview 2024